Ampio Pharmaceuticals, Inc. (AMPE)

USD 0.0

(0.0%)

Market Cap (In USD)

2952.00

Revenue (In USD)

-

Net Income (In USD)

-8.63 Million

Avg. Volume

1645.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-4-2.91
PE
-
EPS
-
Beta Value
3.708
ISIN
US03209T3077
CUSIP
03209T109
CIK
1411906
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Michael A. Martino
Employee Count
-
Website
https://www.ampiopharma.com
Ipo Date
2010-03-31
Details
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.